STERIS Stock - Analyst consensus and sector check on a quiet news day
19.06.2026 - 18:55:59 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:54 UTC. Details in the imprint.
STERIS (IE00BFY8C754) is drawing steady interest from healthcare investors even without a fresh company announcement today. On this quiet Friday, the focus shifts to how the stock is valued versus peers and what analysts currently expect for the medical-technology group.
All news and analysis on STERIS stock
Background reports, historical ad hoc releases and further price data on STERIS stock can be found in the dedicated topic area on ad-hoc-news.de.
What the consensus shows
According to the latest overview on MarketScreener, a majority of analysts covering STERIS currently rate the stock as a Buy, with only a small minority on Hold and virtually none on Sell. MarketScreener consensus data This distribution underlines the broadly positive stance on the mid-cap medical-technology name.
The same consensus data point to expectations of continued double-digit earnings-per-share growth over the next fiscal years, helped by steady procedure volumes and integration synergies from past acquisitions. Analyst forecasts summary That backdrop gives investors a sense of how STERIS is positioned relative to other healthcare equipment makers.
How STERIS compares with peers
Within the wider US healthcare-equipment space, STERIS competes for investor attention with larger names such as Stryker, Becton Dickinson and Baxter. These companies also address hospitals, clinics and life-science customers but with different product mixes and geographic exposures.
Compared with these peers, STERIS typically trades on a valuation that reflects its focus on sterilization and infection prevention, segments seen as structurally important for healthcare systems. On balance, this has historically delivered relatively resilient revenue trends through economic cycles.
Earnings and recent reporting cycle
STERIS last reported results for its fiscal fourth quarter and full year 2025 in early May, highlighting revenue growth and improving margins in core segments, including healthcare and life sciences. STERIS IR news overview Management also commented on demand patterns from hospitals and pharmaceutical customers during that release.
The company additionally used its latest results presentation to update investors on cost initiatives and capacity expansions. Against this backdrop, Friday's quiet tape gives market participants time to digest those earlier messages and align them with the broader sector performance this week.
Sector moves this week
Looking at the broader healthcare-equipment sector, trading has been mixed over the week, influenced by macro data and shifting expectations for US interest-rate cuts. Reuters US markets coverage Some large-cap medical-technology names in the Standard & Poor's 500 index have edged up, while others have seen profit-taking after previous gains.
In that context, STERIS shares sit within a group often viewed as defensive due to the essential nature of sterilization and infection-prevention services. Overall, this positioning can offer a contrast to more cyclical areas of the equity market during periods of higher volatility.
What the company sells
STERIS generates most of its revenue from infection prevention, decontamination and sterilization solutions for hospitals, surgery centers and life-science companies. A representative product line is its sterilization equipment and related consumables, which help healthcare providers maintain stringent hygiene and patient-safety standards worldwide.
Where the stock trades today
The shares of STERIS (IE00BFY8C754) trade on the New York Stock Exchange at $XXX.XX as of 06/19/2026, 16:54 ET.
Key facts on STERIS stock
- Company: STERIS plc
- ISIN: IE00BFY8C754
- WKN: A14U2Z
- Ticker: STE
- Venue: NYSE
- Price (as of 06/19/2026, 16:54 ET): XXX.XX USD
- Market cap: XX.X billion USD (as of 06/19/2026)
- Sector / Industry: Health Care / Health Care Equipment & Supplies
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
